The use of saliva as a biological fluid in relative bioavailability studies: Comparison and correlation with plasma results

Biopharmaceutics and Drug Disposition

Volumn 31, Issue 8-9, 2010, Pages 476-485

  Ruiz, M Esperanza ^a   Conforti, Paula ^a   Fagiolino, Pietro ^b   Volonté, M Guillermina ^a  

^a UNIVERSIDAD NACIONAL DE LA PLATA   (Argentina)

^b UNIVERSIDAD DE LA REPÚBLICA   (Uruguay)

Author keywords

carbamazepine; dissolution profiles; in vitro in vivo correlations; relative bioavailability; saliva

Indexed keywords

CARBAMAZEPINE; DODECYL SULFATE SODIUM;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG SALIVA LEVEL; DRUG SOLUBILITY; FEMALE; HUMAN; HUMAN EXPERIMENT; INTERMETHOD COMPARISON; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TABLET FORMULATION; TIME TO MAXIMUM PLASMA CONCENTRATION;

AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CARBAMAZEPINE; DOSAGE FORMS; DRUG MONITORING; DRUGS, GENERIC; FEMALE; HUMANS; LINEAR MODELS; MALE; SALIVA; SOLUBILITY; TABLETS; THERAPEUTIC EQUIVALENCY;

EID: 78649684747     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.728     Document Type: Article

References (39)

1. Drobitch RK, Svensson CK,. Therapeutic drug monitoring in saliva. An update. Clin Pharmacokinet 1992; 23: 365-379.
2. Aps JK, Martens LC,. Review: The physiology of saliva and transfer of drugs into saliva. Forensic Sci Int 2005; 150: 119-131.
3. Kaufman E, Lamster IB,. The diagnostic applications of saliva-a review. Crit Rev Oral Biol Med 2002; 13: 197-212.
4. Eadie MJ,. Therapeutic drug monitoring-antiepileptic drugs. Br J Clin Pharmacol 2001; 52 Suppl 1: 11S-20S.
5. Ritschel WA, Tompson GA,. Monitoring of drug concentrations in saliva: a non-invasive pharmacokinetic procedure. Methods Find Exp Clin Pharmacol 1983; 5: 511-525.
6. Fagiolino P., Monitorizacion de Farmacos en Saliva: Aplicaciones Biofarmaceuticas, Farmacocineticas y Terapeuticas, 1st edn. Comision Sectorial de Investigacion Cientifica (CSIC) de la Universidad de la Republica: Montevideo, Uruguay, 1999.
7. Posti J,. Saliva-plasma drug concentration ratios during absorption: theoretical considerations and pharmacokinetic implications. Pharm Acta Helv 1982; 57: 83-92.
8. World Medical Association General Assembly. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. J Int Bioethique 2004; 15: 124-129.
9. Pynnonen S,. The pharmacokinetics of carbamazepine in plasma and saliva of man. Acta Pharmacol Toxicol (Copenh) 1977; 41: 465-471. (Pubitemid 8231589)
10. Rosenthal E, Hoffer E, Ben-Aryeh H, Badarni S, Benderly A, Hemli Y,. Use of saliva in home monitoring of carbamazepine levels. Epilepsia 1995; 36: 72-74.
11. Westenberg HG, de Zeeuw RA, van de Kleijn E, Oei TT,. Relationship between carbamazepine concentrations in plasma and saliva in man as determined by liquid chromatography. Clin Chim Acta 1977; 79: 155-161.
12. Rylance GW, Butcher GM, Moreland T,. Saliva carbamazepine levels in children. Br Med J 1977; 2: 1481.
13. MacKichan JJ, Duffner PK, Cohen ME,. Salivary concentrations and plasma protein binding of carbamazepine and carbamazepine 10,11-epoxide in epileptic patients. Br J Clin Pharmacol 1981; 12: 31-37.
14. Mennickent S, Vega M, Godoy CG, Leon MD,. [Saliva and plasma levels of carbamazepine have a poor correlation: a pilot study]. Rev Med Chil 2007; 135: 335-340.
15. Paxton JW, Donald RA,. Concentrations and kinetics of carbamazepine in whole saliva, parotid saliva, serum ultrafiltrate, and serum. Clin Pharmacol Ther 1980; 28: 695-702.
16. Dickinson RG, Hooper WD, King AR, Eadie MJ,. Fallacious results from measuring salivary carbamazepine concentrations. Ther Drug Monit 1985; 7: 41-45.
17. Anderson GD,. Understanding the ramifications of switching among AEDS: what are the data? Adv Stud Med 2008; 8: 229-234.
18. FDA/CDER. Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products-General Considerations. 2003.
19. EMEA/CPMP. Note for Guidance on the Investigation of Bioavailability and Bioequivalence. 2001.
20. Meyer MC, Straughn AB, Jarvi EJ, Wood GC, Pelsor FR, Shah VP,. The bioinequivalence of carbamazepine tablets with a history of clinical failures. Pharm Res 1992; 9: 1612-1616.
21. Jung H, Milán RC, Girard ME, León F, Montoya MA,. Bioequivalence study of carbamazepine tablets: in vitro/in vivo correlation. Int J Pharm 1997; 152: 37-44.
22. Kovacevic I, Parojcic J, Homsek I, Tubic-Grozdanis M, Langguth P,. Justification of biowaiver for carbamazepine, a low soluble high permeable compound, in solid dosage forms based on IVIVC and gastrointestinal simulation. Mol Pharm 2009; 6: 40-47.
23. Olling M, Mensinga TT, Barends DM, Groen C, Lake OA, Meulenbelt J,. Bioavailability of carbamazepine from four different products and the occurrence of side effects. Biopharm Drug Dispos 1999; 20: 19-28.
24. Vázquez M, Fagiolino P, Rubio M, Maletta-Fraile L,. Bioequivalence study between two conventional tablets of carbamazepine using saliva as biological fluid. Eur J Drug Metab Pharmacokinet 1993; special issue: 164-168.
25. The United States Pharmacopeia 31. United States Pharmacopeia Convention: Rockville, MD, 2008.
26. British Pharmacopeia. British Pharmacopeia Commission: London, UK, 2008.
27. Shah VP, Midha KK, Dighe S, et al,. Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies. Conference report. Eur J Drug Metab Pharmacokinet 1991; 16: 249-255.
28. Green JR, Margerison D,. Statistical Treatment of Experimental Data Physical Sciences Data Series, 1st revised edn. Elsevier Scientific: Amsterdam, 1978.
29. Vining RF, McGinley RA,. Hormones in saliva. Crit Rev Clin Lab Sci 1986; 23: 95-146.
30. Rasmussen F,. Salivary excretion of sulphonamides and barbiturates by cows and goats. Acta Pharmacol Toxicol (Copenh) 1964; 21: 11-19.
31. Faigle JW, Brechbühler S, Feldman KF, Richter WJ,. The biotransformation of carbamazepine. In Epileptic Seizures-Behaviour-Pain, Birkmayer W, (ed.). Hans Huber Publishers: Bern/Stuttgart/Viena, 1976; 127-140.
32. McAuliffe JJ, Sherwin AL, Leppik IE, Fayle SA, Pippenger CE,. Salivary levels of anticonvulsants: a practical approach to drug monitoring. Neurology 1977; 27: 409-413.
33. Zapater P, Horga JF,. [Bioequivalence and generic drugs. I. Studies of bioequivalence, considering the theoretical basis, design and use]. Rev Neurol 1999; 29: 1235-1246.
34. Miles MV, Tennison MB, Greenwood RS,. Intraindividual variability of carbamazepine, phenobarbital, and phenytoin concentrations in saliva. Ther Drug Monit 1991; 13: 166-171.
35. Moffat AC, Widdop B, Osselton MD, Clarke EGC,. Clarke's Analysis of Drugs and Poisons: In Pharmaceuticals, Body Fluids and Postmortem Material, 3rd edn. Pharmaceutical Press: London, 2004.
36. Lake OA, Olling M, Barends DM,. In vitro/in vivo correlations of dissolution data of carbamazepine immediate release tablets with pharmacokinetic data obtained in healthy volunteers. Eur J Pharm Biopharm 1999; 48: 13-19.
37. Veng-Pedersen P, Gobburu JV, Meyer MC, Straughn AB,. Carbamazepine level-A in vivo-in vitro correlation (IVIVC): a scaled convolution based predictive approach. Biopharm Drug Dispos 2000; 21: 1-6.
38. Sathe P, Tsong Y, Shah VP,. In vitro dissolution profile comparison and IVIVR. Carbamazepine case. Adv Exp Med Biol 1997; 423: 31-42.
39. Lindenberg M, Kopp S, Dressman JB,. Classification of orally administered drugs on the World Health Organization Model List of Essential Medicines according to the biopharmaceutics classification system. Eur J Pharm Biopharm 2004; 58: 265-278.